New Frontiers, Challenges, and Evolving Treatment Paradigms for Iron Deficiency Anemia (IDA)

The Evolving and Complex Landscape of Detecting, Assessing, and Managing Iron Deficiency Anemia in the Oncology and Hematology Specialty Setting - CME Course

The Evolving and Complex Landscape of Detecting, Assessing, and Managing Iron Deficiency Anemia in the Oncology and Hematology Specialty Setting -

Causes, Disease Burden, Complications and Mandates for Safe, Convenient, and Definitive Management of IDA Ralph V. Boccia, MD, FACP - Program Chair
Ralph V. Boccia, MD, FACP

Ralph V. Boccia, MD, FACP

Consultative Challenges in the Diagnosis and Management of Iron Deficiency Anemia (IDA) Across the IDA Morbidity Continuum: Video

Consultative Challenges in the Diagnosis and Management of Iron Deficiency Anemia (IDA) Across the IDA Morbidity Continuum:

Patient Profiles, Etiologies of IDA, Clinical Controversies, and Comparative Efficacy of Oral and IV Iron Repletion - David H. Witt, MD
David Witt, MD

David Witt, MD

Assistant Professor of Medical Oncology
Real World Implications of Oral versus IV Iron Repletion: What Do the Latest Clinical Trials Teach Us? How Do They Guide Us?: Video

Real World Implications of Oral versus IV Iron Repletion: What Do the Latest Clinical Trials Teach Us? How Do They Guide Us?:

Indications, Triggers, and Practical Approaches for Ensuring Safe, Effective, and Predictable IV Iron Repletion in the Cancer Patient - Nashat Gabrail, MD
Nashat Gabrail, MD

Nashat Gabrail, MD

President of Gabrail Cancer Center, Ohio
Evolving Needs and Strategies for the Hematology Consultant: Late-Breaking Trials and Guidelines for IV Iron Repletion in the Setting of Heart Failure: Video

Evolving Needs and Strategies for the Hematology Consultant: Late-Breaking Trials and Guidelines for IV Iron Repletion in the Setting of Heart Failure:

A Trial-to-Therapy Analysis for the Hematology Specialist -Ralph V. Boccia, MD, FACP - Program Chair
Ralph Boccia, FACP, MD

Ralph Boccia, FACP, MD

Medical Director, Center for Cancer and Blood Disorders
Interactive Discussion and Dialogue Video

Interactive Discussion and Dialogue

Faculty Panel
Ralph Boccia, FACP, MD

Ralph Boccia, FACP, MD

Medical Director, Center for Cancer and Blood Disorders
David Witt, MD

David Witt, MD

Assistant Professor of Medical Oncology
George Rodgers III, MD, PhD

George Rodgers III, MD, PhD

Professor, Division of Hematology and Hematologic Malignancies at Huntsman Cancer Institute
Nashat Gabrail, MD

Nashat Gabrail, MD

President of Gabrail Cancer Center, Ohio

Program Medium

Internet-based program

 

Estimated Time to Complete Educational Activity

2.5 hours

 

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the management of iron deficiency anemia.

Release Date: January, 6, 2017

Expiration Date: January 6, 2019

 

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period January 6, 2017  through January 6, 2019 participants must:
1) read the learning objectives and faculty disclosures;
2) study the educational activity, and are expected to view all 9 segments totaling 1.5 hours to successfully complete the activity and earn CME credit;
3) register and complete the evaluation form and post-test;
4) score 100% on the post-test; and
5) print out your CME certificate.

 

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

 

Grantor Support

Supported by an educational grant from American Regent, Inc.

 

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. ‘The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physician.

 

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Policy on Faculty & Provider Disclosure

University of Massachusetts Medical School requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to University of Massachusetts Medical School policy.  The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

 

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.

 

Program Faculty and Disclosure

RALPH V. BOCCIA, MD, FACP
(Program Co-Chair)
Clinical Associate Professor of Medicine
Georgetown University
Medical Director
Center for Cancer and Blood Disorders

Speaker’s Bureau and Grant/Research Support: AMAG, American Regent

DAVID WITT, MD 
Yale School of Medicine 
New Haven, CT 

Nothing to disclose

NASHAT GABRAIL, MD
President 
Gabrail Cancer Center 
Canton, OH

Nothing to disclose

GEORGE M. RODGERS, III, MD, PhD
Professor, Division of Hematology and Hematologic Malignancies
Huntsman Cancer Institute
University of Utah
Adjunct Professor, Department of Pathology
Medical Director, Coagulation Laboratory
ARUP Laboratories 

Consultant: AMAG
Grant/Research Support: Luitpold

 

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Evaluate and manage cancer patients with iron deficiency anemia (IDA), and better understand the rationale for, comparative features, and clinical importance of IV iron repletion in this high risk population of cancer patients
  • Describe the causes of and challenges of treating IDA in patients with cancer
  • Distinguish among and deploying IV iron formulations; and administer such agents, from a practical and safe and convenient perspective, within the framework of a cancer clinic, office-based cancer practice, and/or cancer-linked infusion center
  • Detail relevant mechanistic, clinical, pharmacologic, and radiographic aspects of a new generation of IV iron formulations and align specific formulations for specific patients with cancer
  • Explain the chemistry, comparative features, pharmacology, and toxicology of IV iron formulations

 

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

 

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.

• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.

• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.

• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.

• You should check this privacy policy periodically to see whether we have made any changes